Both CXCL10 and IFNγ are increased in patients with MASLD and linked with development of steatohepatitis and fibrosis [57,58], which could partially explain their increased levels in septic patients. The gene discussed is CXCL10; the disease is metabolic dysfunction-associated steatotic liver disease.